Anthos Therapeutics, based in Cambridge, has a drug in late-stage clinical trials aimed at preventing strokes and blood clots ...

Novartis is buying Anthos Therapeutics from Blackstone’s drug development division, as it makes a bet on an experimental drug aimed at preventing strokes in patients with an irregular heart rhythm.

Novartis is buying Anthos Therapeutics from Blackstone’s drug development division, as it makes a bet on an experimental drug aimed at preventing strokes in patients with an irregular heart rhythm.

With its Q4 2024 financials on Friday, Novartis (NYSE:NVS) (OTCPK:NVSEF) indicated a delayed timeline for initial data from a Phase 3 trial for a cardiac therapy it co-develops with Ionis ...

TD Cowen analyst Steve Scala reiterated a Hold rating on Novartis (NVS – Research Report) today and set a price target of $125.00. The company’s shares opened today at $106.18. According to ...

One of the most important launches for Novartis in recent years is off with a bang. Following a broad FDA approval for the adjuvant treatment of HR-positive, HER2-negative early breast cancer in ...

(Bloomberg) — Novartis AG said profit will rise this year as new medicines help offset competition from copycats of its best-selling drug. Core operating profit will likely grow by a high ...

Novartis Q4 earnings beat estimates with sales up 16%, driven by strong demand for Entresto, Kesimpta, and Cosentyx. CEO Narasimhan reportedly downplays Entresto's U.S. patent expiration ...

Novartis NOVN-0.90%decrease; red down pointing triangle forecasts further profit and sales growth this year after beating analysts’ expectations in the fourth quarter of 2024, despite looming ...

In a report released today, James Quigley from Goldman Sachs maintained a Hold rating on Novartis AG (NOVN – Research Report), with a price target of CHF100.00. According to TipRanks ...

Novartis has finally given up on iscalimab after deciding that the anti-CD40 antibody is not worth pursuing in Sjögren’s syndrome. On a fourth-quarter earnings call with the media this morning ...

After parting ways with BeiGene in 2023, Novartis effectively bowed out of the PD-1 race. Now, the rising class of bispecifics opened up an opportunity for the Swiss pharma to reenter the space ...